Hrubá marža spoločnosti Financière de Tubize SA
Aká je hodnota metriky Hrubá marža spoločnosti Financière de Tubize SA?
Hodnota metriky Hrubá marža spoločnosti Financière de Tubize SA je -22,250.00%
Aká je definícia metriky Hrubá marža?
Hrubá marža (Gross margin) je rozdiel medzi príjmami a nákladmi na predaný tovar vydelený príjmami a vyjadrený v percentách.
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
Hrubá marža spoločností v sektore Health Care sektor na EURONEXT v porovnaní so spoločnosťou Financière de Tubize SA
Čomu sa venuje spoločnosť Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Firmy s metrikou hrubá marža podobnou spoločnosti Financière de Tubize SA
- Hodnota metriky Hrubá marža spoločnosti Magnis Resources je -45,793.10%
- Hodnota metriky Hrubá marža spoločnosti Pure Minerals je -44,700.00%
- Hodnota metriky Hrubá marža spoločnosti Condor Technologies NV je -41,600.00%
- Hodnota metriky Hrubá marža spoločnosti CytoDyn je -27,547.74%
- Hodnota metriky Hrubá marža spoločnosti Aqua Metals Inc je -25,028.00%
- Hodnota metriky Hrubá marža spoločnosti Alpha HPA je -22,812.50%
- Hodnota metriky Hrubá marža spoločnosti Financière de Tubize SA je -22,250.00%
- Hodnota metriky Hrubá marža spoločnosti Hannans je -20,600.00%
- Hodnota metriky Hrubá marža spoločnosti Neovacs S.A je -20,146.52%
- Hodnota metriky Hrubá marža spoločnosti LQwD FinTech je -20,000.00%
- Hodnota metriky Hrubá marža spoločnosti Interlapse Technologies je -20,000.00%
- Hodnota metriky Hrubá marža spoločnosti GOLO Mobile je -19,675.47%
- Hodnota metriky Hrubá marža spoločnosti Coastal Greenland je -18,994.50%